DSIP (10 mg Vial) Dosage Protocol

Dosing & Reconstitution Overview

DSIP (Delta Sleep-Inducing Peptide) is a small nonapeptide first isolated from cerebral venous blood and studied for its influence on slow-wave sleep and the stress response. The figures below are compiled strictly for laboratory and educational reference — they describe how the compound has been handled and dosed in the published literature, not a recommendation for use in humans or animals.

For a 10 mg vial, adding 3.0 mL of bacteriostatic water yields a concentration of approximately 3.33 mg/mL (3,333 mcg/mL). At that concentration, every 0.01 mL drawn on a U-100 insulin syringe equals 1 unit and delivers roughly 33 mcg of material, so a 100 mcg measure corresponds to about 3 units (0.03 mL). Because DSIP is studied at microgram quantities, a larger diluent volume is used to keep these small draws readable on the syringe barrel.

Standard (Gradual) Titration Schedule

The gradual schedule mirrors the conservative escalation seen in the sleep-research literature, where the daily evening amount is stepped up week by week to gauge tolerability before settling into a maintenance band of 250–300 mcg.

Reconstitution Steps

1. Let the sealed lyophilized vial and the bacteriostatic water reach room temperature, then wipe both stoppers with an alcohol swab.
2. Draw 3.0 mL of bacteriostatic water and inject it slowly down the inside wall of the vial — never directly onto the powder pellet.
3. Swirl gently until fully dissolved. Do not shake; aggressive agitation can shear the peptide.
4. The solution should be clear and colourless. Label the vial with the concentration (3.33 mg/mL) and the reconstitution date.
5. Store upright under refrigeration between uses and draw subsequent volumes with a fresh sterile syringe each time.

Advanced (Extended) Schedule

An extended schedule holds the upper maintenance dose for a longer modelling window rather than escalating beyond the published ceiling. DSIP is consistently described at microgram quantities, so the "advanced" variation lengthens the run instead of pushing concentration higher.

Supplies Needed

• DSIP vials (10 mg): ~1 vial for an 8-week run; ~2 vials for a 12-week run at the upper maintenance band.
• Insulin syringes (U-100, 30–50 unit): ~56 for an 8-week daily schedule; ~84 for 12 weeks (one fresh syringe per draw).
• Bacteriostatic water (10 mL): a single bottle covers both the 8- and 12-week schedules.
• Alcohol swabs: ~112 for 8 weeks and ~168 for 12 weeks (one per draw, plus stopper wipes).

Protocol Overview

• Research goal: model modulation of slow-wave (delta) sleep and the hypothalamic-pituitary-adrenal stress response.
• Schedule: once-daily subcutaneous administration in the evening, roughly 30–60 minutes before the rest period.
• Dose band: 100–300 mcg daily.
• Fill: 10 mg lyophilized, reconstituted to 3.33 mg/mL with 3 mL diluent.
• Storage: −20 °C dry; 2–8 °C once reconstituted.

Dosing Protocol Notes

• Begin at the lowest 100 mcg step and step up weekly only after tolerability is established.
• Keep administration at a fixed evening time for consistent exposure relative to the rest cycle being modelled.
• Hold the 250–300 mcg maintenance band rather than chasing higher concentrations.
• DSIP has a short circulating half-life, which is why the published model favours daily rather than weekly dosing.

Storage Instructions

Keep sealed lyophilized vials at −20 °C, protected from light, where stability extends for many months. Once reconstituted, refrigerate at 2–8 °C and use within a few weeks. Allow refrigerated solution to warm slightly before drawing, avoid repeated freeze-thaw cycles, and aliquot if a vial will be sampled many times.

Important Handling Notes

• Use a sterile syringe for every draw and never re-enter the vial with a used needle.
• Because each draw is tiny (3–9 units), read the syringe carefully and avoid over-pull.
• Rotate handling technique to keep the stopper intact across many small withdrawals.
• Document each draw — date, volume, remaining material — for reproducibility.

How DSIP Works

DSIP is a nine-amino-acid peptide that acts as a neuromodulator rather than a classic hormone. It crosses the blood-brain barrier and has been associated in EEG studies with increased delta-wave (slow-wave) sleep, which is why it carries the "delta sleep-inducing" name. Beyond its sleep signature, DSIP appears to interact with the hypothalamic-pituitary-adrenal axis, attenuating ACTH and corticosterone release in animal models and thereby blunting elements of the stress response. Its precise receptor target remains incompletely characterised, and much of the available data comes from older European neurology and biobehavioural research.

Reported Benefits & Side Effects

Benefits observed in research

• Increased slow-wave (delta) sleep duration and improved sleep architecture on EEG.
• Reported normalisation of disrupted sleep patterns in chronic-insomnia study cohorts.
• Possible stress-response dampening through HPA-axis modulation.
• A notably wide safety margin — animal studies identified no lethal dose.

Side effects reported

• Generally mild and transient — occasional headache or nausea.
• Occasional mild injection-site reactions such as redness or itching.
• No serious dose-limiting toxicity documented in the available literature.

Supporting Lifestyle Factors (Research Context)

• Consistent sleep-wake timing and a dark, cool rest environment as standard study controls.
• Limited evening light and stimulant exposure, which interact with the sleep variables being modelled.
• Stress-management and relaxation routines, given the peptide's HPA-axis focus.

Injection Technique (Reference Only)

• Prepare the vial and site with alcohol swabs and let them dry.
• Insert subcutaneously at a 45–90° angle depending on needle length; aspiration is not required for subcutaneous work.
• Because volumes are small, a single site is usually sufficient per dose.
• Rotate sites systematically and dispose of sharps in an approved container.

References

Related Protocols